Target intelligence / Profile preview

Parkin coregulated gene protein (PACRG)

Target
PACRG
Molecular classification
Microtubule-associated protein, Axonemal protein, Molecular chaperone/chaperonin-binding protein, Adaptor/scaffold protein (for LUBAC complex)
01

Overview

PACRG (Parkin coregulated gene protein) is an evolutionarily conserved protein encoded by the PACRG gene, closely co-regulated with the adjacent PRKN (Parkin) gene via a bidirectional promoter. It forms large molecular complexes with heat shock proteins and chaperonin components and localizes to the axonemal doublet microtubules in cilia and flagella, where it is essential for microtubule stability and motility. PACRG plays roles in neuronal survival by suppressing cell death triggered by unfolded Pael receptor and is a component of Lewy bodies found in Parkinson's disease brains. It also facilitates TNF-induced NF-κB signaling by stabilizing the LUBAC complex, substituting for the adaptor protein SHARPIN and protecting cells from apoptosis triggered by TNF. Genetic variations in PACRG, especially in its regulatory regions, are linked to increased susceptibility to leprosy and possibly other intracellular infections. There are currently no known drugs directly targeting PACRG, and its role as a therapeutic target has not been established in clinical practice.

Other names
PACRGParkin coregulated gene proteinPARK2CRGGLUPHAK005771FLJ32724BUG21pf12PACRG2.1molecular chaperone/chaperonin-binding protein
02

Mechanism of action

Not applicable (no known drugs) as PACRG is not an established target for therapeutic intervention

03

Biological functions

Stabilization of microtubule doublets in cilia and flagella (axoneme stability)Regulation of ciliary/flagellar motilitySuppression of unfolded Pael receptor-induced neuronal deathFormation of large molecular complexes with chaperone proteins (HSP70, HSP90)Component of Lewy bodies in Parkinson's diseasePositive regulation of TNF-induced NF-κB signaling via linear ubiquitination (LUBAC complex)
04

Disease associations

Neurodegenerative disease (Parkinson's disease, component of Lewy bodies; early-onset Parkinson’s disease)Infection (increased susceptibility to leprosy and intracellular pathogens)Male infertility (defective sperm flagella in PACRG-deficient mice)
05

Safety considerations

No known safety concerns for direct targeting as no drugs are developed/approved against PACRG. Genetic or functional disruption may lead to neurodegenerative phenotypes or ciliary defects
06

Biomarkers

Presence of PACRG protein in Lewy bodies in Parkinson’s disease (could be considered a marker for disease pathology rather than for patient selection or therapeutic efficacy)

Beyond the preview

Go deeper on Parkin coregulated gene protein (PACRG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Parkin coregulated gene protein (PACRG).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call